Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation

Opinion
Video

Hussein Tawbi, MD, PhD, explains that for BRAF-mutated metastatic melanoma, treatment options include checkpoint inhibitors, single-agent and combination IO therapies, and BRAF and MEK inhibitor combinations, offering varying response rates and progression-free survival periods.

Related Videos
Related Content